SCoV-2 *Detect*™ IgG ELISA

FDA Emergency Use Authorized

InBios

Innovative Diagnostics for Infectious Diseases

INBIOS INTERNATIONAL, INC.

307 Westlake Ave. N.
Suite 300
Seattle, WA 98109

Phone: 206-344-5821

E-mail:
inquiries@inbios.com

100% Manufactured in the USA

13485-2016 Certified

SCoV-2 *Detect*™ IgG ELISA detects IgG antibodies to SARS-CoV-2, the virus that causes COVID-19, in human serum. Antibody testing for COVID-19 is needed to understand the pervasiveness of the disease within communities.

This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity.

Features

- Sensitivity: 97.8%
- Specificity: 98.9%
- No specific analyzer required-versatile for many qualified laboratories
- Kit includes a 96 well plate with all necessary reagents and controls
- Tests 90 unknown specimens
- Time to result - approximately 2.5 hours

About COVID-19

COVID-19 is the infectious disease caused by the most recently discovered coronavirus; it is now a pandemic affecting many countries globally. People can catch COVID-19 from others who have the virus. The disease spreads primarily from person to person through small droplets from the nose or mouth, which are expelled when a person with COVID-19 coughs, sneezes or speaks.

Ordering Information

Catalog No.	Format	Quantity/Kit	Time to Result	Storage	Shelf Life
COVE-G	Indirect	96 wells/plate	~2 hours	2-8°C	12 months

For more info about this kit and other InBios COVID-19 products, visit www.inbios.com/covid-19

Please note: this test (EUA number 201632) has not been FDA cleared or approved; has been authorized by FDA under an EUA for use by authorized laboratories; has been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens; and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.